Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country
- Resource Type
- Authors
- Ganesh Kumar Vishwanathan; Jasmita Dass; Rishi Dhawan; Pradeep Kumar; Mukul Aggarwal; Tulika Seth; Manoranjan Mahapatra; Seema Tyagi; Jayastu Senapati
- Source
- Leukemialymphoma. 62(6)
- Subject
- Oncology
Cancer Research
medicine.medical_specialty
Myeloid
Combination therapy
Azacitidine
Disease
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
hemic and lymphatic diseases
Internal medicine
Medicine
Humans
Developing Countries
Sulfonamides
business.industry
Venetoclax
Myeloid leukemia
Hematology
medicine.disease
Bridged Bicyclo Compounds, Heterocyclic
Leukemia
Leukemia, Myeloid, Acute
medicine.anatomical_structure
chemistry
030220 oncology & carcinogenesis
Stem cell
business
030215 immunology
medicine.drug
- Language
- ISSN
- 1029-2403
Despite improvements in leukemia therapy, acute myeloid leukemia (AML) remain a difficult disease to treat with a majority of patients having disease relapse without an allogeneic stem cell transpl...